PURPOSE: The aim of the study was to evaluate the feasibility and efficacy of the combination of @entity2664 , @entity3118 , @entity2592 , and @entity900 (MIFAP) in @entity1 with prognostically unfavorable recurrent and @entity978 ( @entity978 ) and @entity1893 ( @entity1893 ). METHODS: Forty-six @entity1 (median age 43 years, range 18-63) with relapsed (n = 15) or refractory (n = 31) @entity706 were enrolled ( @entity978 , n = 13; low-grade/transformed @entity1893 , n = 4; high-grade @entity1893 , n = 29). A total of 39 @entity1 (85%) showed multiply @entity66 with a duration of prior remission of < 12 months (n = 8) or had @entity706 being resistant to prior chemotherapy (n = 31). The MIFAP therapy consisted of @entity3118 (15 mg/m2, q. 12 h, day 1-4), @entity2592 (50 mg/m2 by continuous infusion (CI) over 22 h, day 1-4), @entity900 (25 or 30 mg/m2 by CI over 24 h, day 1-4), and @entity2664 (4 mg/m2, day 2-5). RESULTS: Thirteen @entity1 (28%) achieved complete remission (CR) and 15 @entity1 (33%) partial remission (PR), for an overall response (OR) rate of 61%. Twenty-two @entity1 responding to MIFAP (10 CR, 12 PR) have been consolidated by high-dose therapy (HDT) with hematopoietic @entity8 ( @entity8 ). After a median follow-up of 12 months, 16 @entity1 are in continuous CR (CCR) (n = 14) or CCRu (unconfirmed) (n = 2). The median duration of event-free survival (EFS) and @entity1349 ( @entity1349 ) were 6.5 and 19.3 months, respectively. Probabilities of EFS and @entity1349 after 3 years were 19% and 40%. Responders consolidated by subsequent HDT showed rates for 3-year EFS and @entity1349 of 40% and 66%, respectively. Unfavorable prognostic factors for EFS by univariate analysis were @entity706 and the presence of @entity1109 . Significant prognostic factors for @entity1349 were @entity1893 , @entity706 , @entity1109 , and bone marrow involvement. The major @entity137 were @entity1431 and @entity882 of the World Health Organization (WHO) grade IV in nearly all courses (median duration 10 and 11 days). In contrast, non-hematological side effects were moderate, predominantly of WHO grades I and II. Treatment-related mortality with MIFAP was 4% (two @entity1 with @entity295 by @entity54 ). CONCLUSIONS: MIFAP is an effective salvage protocol for @entity1 with poor-risk recurrent or refractory @entity978 and @entity1893 . The observed @entity137 seems to be acceptable considering the unfavorable prognosis and intensive pretreatment. The results in @entity1 responding to MIFAP and afterwards undergoing HDT with autologous stem cell support are even comparable to those published in @entity1 with prognostically more @entity66 .

Salvage chemotherapy with @entity2664 , @entity3118 , @entity2592 , and XXXX (MIFAP) in relapsing and @entity706 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'toxicity'] @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['favorable diseases', 'relapsed diseases'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'refractory lymphoma', 'malignant lymphoma'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity1109 :: ('MESH:D012678', 'Disease') :: ['B-symptoms'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity3118 :: ('MESH:C024352', 'Chemical') :: ['fludarabine'] @entity54 :: ('746128', 'Species') :: ['Aspergillus fumigatus'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukocytopenia'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity978 :: ('MESH:D006689', 'Disease') :: ['HD', "refractory Hodgkin's disease"] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity900 :: (MESH:D002945,Chemical) :: ['cisplatin']
